anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Choledocholithiasis refers to the presence of gallstones within the common bile duct. It is proposed to look for markers that help in the diagnosis and in differentiating between retained and migrated gallstones. The selection of patients to perform endoscopic retrograde cholangiopancreatography (ERCP) is a very important aspect, due to the economic aspects and possible complications. By making a proper patient selection for additional studies or procedure, then the costs, complications and days of stay would be reduced. Avoiding the unnecessary use of ERCP would avoid its complications. Taking advantage of the development of technology, the improvement in computer systems, the use of artificial intelligence and a Symbolic Regression Model that works to predict the presence of choledocholithiasis and provide evidence that clarifies the treatment of patients with this pathology, especially in this group where there is a bigger controversy.

Having the historical database of the University Hospital (HU), regarding clinical, laboratory and image variables of patients with suspected choledocholithiasis, using a symbolic regression method, several randomly formed equations are generated. Each equation deducts its coefficient of linear correlation (Pearson's correlation).

For the following study we admitted to the emergency department of adults at the University Hospital all patients with clinical suspicion of choledocholithiasis, who meet the inclusion criterion. The study which is realized is a normal one based on the method of clinical predictors, obtaining laboratory studies, image studies, and patient management will be carried out based on the method of clinical predictors. The calculation is made with the equation obtained, and the patient is monitored until discharge. The calculation obtained from the equation will not be taken into account for the decisions in the management of the patient. The variables studied as white blood cells, total bilirubin values, direct bilirubin, indirect bilirubin, Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST), alkaline phosphatase (AP), gamma-glutamyl transpeptidase (GGT) at admission will be taken from the clinical record. Transabdominal ultrasonography will be performed upon admission by the diagnostic radiology department of the HU and the size of the bile duct in mm, presence of gallbladder gallstones and bile duct stones will be taken from the report. ERCP, magnetic resonance cholangiopancreatography (MRCP) or intraoperative cholangiography will be performed and one will be taken as a confirmation of choledocolithiasis, and its absence would rule it out.
BACKGROUND: Scoliosis constitutes a prevalent comorbidity in adolescents with polyhandicap and frequently leads to other severe impairments, impacting abilities and requiring complex caregiving strategies. Therefore, spinal fusion surgeries are commonly performed to alleviate pain and provide more comfort. However, spine stabilization has not previously been proven to improve the severity health status of adolescents with polyhandicap according to specific clinical scales.
OBJECTIVE: This study describes and compares the severity health status of adolescents with polyhandicap before and after they underwent spinal fusion.
METHODS: A monocentric retrospective observational study was conducted in the university hospital centre of Saint-Etienne, France. We included between 2009 to 2020, 30 scoliotic adolescents with polyhandicap who underwent spinal fusion performed with the same surgical technique and the same surgeon. The main outcome was the variation in the Polyhandicap Severity Scale (PSS) score after surgery. Secondary outcomes were variations in PSS subscores, quality of life scores, fronto-sagittal X-ray parameters, and measures of surgical complication rates and lengths of stay.
RESULTS: Among 30 adolescents, 27 PSS analyses were performed. We found a significant improvement between pre- and postoperative PSS scores, mainly for pain and respiratory, digestive, and skin disabilities. These improvements were accompanied by significant reductions in pelvic obliquity, in frontal and sagittal curves. The mean hospital length of stay was 45 days. During postoperative period, patients received a personalized postoperative rehabilitation procedure with spasticity and pain treatments, physiotherapy, and verticalization (wheelchair sitting and positioning devices such as contoured seat intended to increase postural stability). The mortality rate was estimated at 7%. At least 1 complication per patient occurred.
CONCLUSIONS: We show that spinal fusion surgeries confer a significant improvement in the severity health status in scoliotic adolescents with polyhandicap.
Systems, methods, and apparatus for processing cell therapy products are provided. A closed system can include a container, an expandable seal, a connector, and a needle for aspirating. The container can have an interior configured to hold at least one cellular therapy product. The expandable seal can be coupled to the container and form a barrier between an external environment and the interior of the container. The connector can be coupled to the expandable seal. The needle can be operatively coupled to the connector, and a distal end of the needle can extend from the connector into the interior of the container. The position of the distal end of the needle can be selectively adjusted between a first depth in the interior of the container and a second depth in the interior of the container without exposing the needle to the external environment.
Compositions for generating antimicrobial activity comprising a purified enzyme that is able to convert a substrate to release hydrogen peroxide, and a sugar substance that includes a substrate for the enzyme. The compositions do not include sufficient free water to allow the enzyme to convert the substrate. The sugar substance is an unrefined natural sugar substance and the enzyme is an oxidoreductase enzyme. The exemplified sugar substance is pasteurized honey and the exemplified enzyme is glucose oxidase. Use of the compositions to treat microbial infections and wounds is described, as well as methods for their production. The treatment of acne, chaffed lips, infected eczema, fungal nail infections, pressure sores, infected ulcers, Caesarian wounds, infections at line entry points, such as catheters, as well as general wound treatment.
PURPOSE:To provide a bath agent composition having excellent skin-beautifying activity, heat-insulating activity, deodorant activity and long period stability by compounding a horse oil or citrus fruit seed oil. CONSTITUTION:A bath agent composition contains 0.1-80 pts.wt. of a horse oil or 1-80 pts.wt. of a citrus fruit seed oil. The house oil is prepared by extracting the fat portion of a horse and simultaneously filtering the extracted fat fraction, wherein the extraction is performed by employing a fatty solvent but preferably by thermally eluting out the fat portion. The bath agent composition containing the house oil is not shaped into spheres due to the good dispersibility thereof, gives a flexible touch to all skin area of a bathing man and gas an excellent heat-insulating activity and a remarkable activity in which the bath agent composition is slightly adhered to bath tubs. The citrus fruit seed oil can inexpensively and stably be supplied because of being prepared from the wasted seeds and has excellent skin-beautifying activity and deodorant activity. The bath agent composition has highly excellent dispersibility into hot water and gives a dry comfortable touch to skin.
BACKGROUND: Tyrosine kinase inhibitor (TKI) treatment has been identified to be a risk factor for metabolic syndrome and cardiovascular diseases (CVDs) in patients diagnosed with chronic myeloid leukemia (CML). However, the specific contribution of post-TKI metabolic syndrome and the individual TKIs, including imatinib, nilotinib, and dasatinib, contribute to the development of CVDs remains unclear.
METHODS: We conducted a nationwide database to investigate the incidence of post-TKI metabolic syndrome, including diabetes, hyperlipidemia, and hypertension, as well as their association with CVDs. To compare the risk of post-TKI comorbidities and CVDs among TKIs, we utilized the incidence rate ratio (IRR), and subdistribution hazard ratio (SHR) calculated from multiple Fine-Gray models.
RESULTS: A total of 1211 patients without diabetes, 1235 patients without hyperlipidemia, and 1074 patients without hypertension were enrolled in the study. The incidence rate of post-TKI diabetes and hyperlipidemia was the highest in patients treated with nilotinib compared to imatinib and dasatinib (IRRs ≥ 3.15, Ps ≤ .047). After adjusting for confounders, nilotinib remained a significant risk factor for post-TKI diabetes and hyperlipidemia at an SHR of 3.83 (P < .001) and 5.15 (P < .001), respectively. Regarding the occurrence of CVDs, patients treated with nilotinib were more likely to develop CVDs than those treated with imatinib in non-hyperlipidemic group (IRR = 3.21, P = .020). Pre-existing and post-TKI hyperlipidemia were found to have a stronger association with CVDs, with SHR values of 5.81 (P = .034) and 13.21 (P = .001), respectively.
CONCLUSION: The findings of this study indicate that nilotinib treatment is associated with increased risks of diabetes and hyperlipidemia, with hyperlipidemia being the most significant risk for CVDs. Therefore, we recommend that CML patients receiving nilotinib should undergo screening for diabetes and hyperlipidemia prior to initiating TKI treatment. Additionally, regular monitoring of lipid profiles during TKI therapy and implementing effective management strategies to control hyperlipidemia are crucial.
Disclosed herein is a personal care conditioning and/or styling composition for keratin substrate comprising: (A) at least one conditioning and/or styling copolymer obtained from polymerizing: (i) about 0.1 wt. % to 99.9 wt. % of at least one cationic or pseudo-cationic monomer selected from the group consisting of acrylamidopropyl trimethylammonium chloride (APT AC) and/or diallyl dimethyl ammonium chloride (DADMAC); and (ii) about 0.1 wt. % to 99.9 wt. % of at least one monomer comprising at least one functionalized or unfunctionalized acryloyl moiety and at least one lactam moiety; (B) at least one cosmetically acceptable excipient; and (C) optionally, at least one effective amount of personal care active ingredient. Also disclose is a process for preparing such composition and method of use thereof.
PURPOSE: To obtain a surfactant/perfume oil mixture suitable to prepare a clear O/W microemulsion. CONSTITUTION: This microemulsion contains a perfume oil, a water phase and a mixture of on or more surfactant having 9 to 18 HLB and one or more assistant surfactants. At least 0.5 wt.% of the assistant surfactants consist of an ionic assistant surfactant. The weight ratio of the perfume oil to the whole surfactants is 0.85 to 2.5, and preferably >=1. The amt. of the perfume oil is preferably 0.01 to 40 wt.% of the microemulsion, preferably at least 50 wt.%. The microemulsion contains <10 wt.%, preferably <5 wt.% alcohols. The surfactants are a nonion type. The obtd. microemulsion is suitable to add aroma to skin or hair for which the amt. of an org. solvent should by controlled as small as possible.
INTRODUCTION: As paediatric intensive care unit (PICU) mortality declines, there is growing recognition of the morbidity experienced by children surviving critical illness and their families. A comprehensive understanding of the adverse physical, cognitive, emotional and social sequelae common to PICU survivors is limited, however, and the trajectory of recovery and risk factors for morbidity remain unknown.
METHODS AND ANALYSIS: The Post-Intensive Care Syndrome - paediatrics Longitudinal Cohort Study will evaluate child and family outcomes over 2 years following PICU discharge and identify child and clinical factors associated with impaired outcomes. We will enrol 750 children from 30 US PICUs during their first PICU hospitalisation, including 500 case participants experiencing ≥3 days of intensive care that include critical care therapies (eg, mechanical ventilation, vasoactive infusions) and 250 age-matched, sex-matched and medical complexity-matched control participants experiencing a single night in the PICU with no intensive care therapies. Children, parents and siblings will complete surveys about health-related quality of life, physical function, cognitive status, emotional health and peer and family relationships at multiple time points from baseline recall through 2 years post-PICU discharge. We will compare outcomes and recovery trajectories of case participants to control participants, identify risk factors associated with poor outcomes and determine the emotional and social health consequences of paediatric critical illness on parents and siblings.
ETHICS AND DISSEMINATION: This study has received ethical approval from the University of Pennsylvania Institutional Review Board (protocol #843844). Our overall objective is to characterise the ongoing impact of paediatric critical illness to guide development of interventions that optimise outcomes among children surviving critical illness and their families. Findings will be presented at key disciplinary meetings and in peer-reviewed publications at fixed data points. Published manuscripts will be added to our public study website to ensure findings are available to families, clinicians and researchers.
TRIALS REGISTRATION NUMBER: NCT04967365.
1375986 Macrolide antibiotic compositions JULIUS SCHMID INC 23 Nov 1971 54462/71 Heading ASB A macrolide antibiotic dosage form consists of a pharmaceutical capsule containing a multiplicity of beadlets (which term includes beads, granules, and pilules) which are composed of: (i) a polyenic macrolide and (ii) an absorbent material capable of binding the macrolide under acid conditions and releasing it under substantially neutral conditions, the weight ratio of (i) to (ii) being from 1:2 to 1:8. The macrolide may be a hexaene or heptaene macrolide e.g. candicidin, fungimycin, hamycin or mediocidin and the absorbent material may be a salt or base of a di- or tri-valent metal e.g. a carbonate, phosphate, sulphate, silicate or hydroxide of Ca, Al, Mg, Bi or Fe, a cellulose derivative, gum or ion exchange resin. The beadlets may be prepared by known methods and may be given an enteric coating, e.g. of a fatty or waxy material.
PURPOSE: A composition containing black currant anthocyanin is provided to suppress collagenase activity and wrinkles and aging and to ensure elasticity. CONSTITUTION: A composition for preventing and treating skin wrinkling contains currant extract as an active ingredient. The currant extract is Ribes nigrum extract. The Ribes nigrum extract is black currant anthocyanins. An external use formulation contains the currant extract or black currant anthocyanine as an active ingredient. An inhibitor for collagenase contains the currant extract as an active ingredient.
1323362 Polymyxin derivatives RHONEPOULENC SA 4 Aug 1970 [5 Aug 1969] 37632/70 Headings C2A and C2C Novel cyclic polypeptides having the general Formula I wherein Y-Z represents one of the amino acid chains D-Leu-Thr, D-Phe-Leu, D-Leu- Leu and D-Leu-Ileu ; G is a radical of Formula II: Py-CH 9 -O-CO- in which Py is pyridyl or pyridyl-N-oxide optionally substituted by a methyl group, Dab represents α,γ-diaminobutyric acid, Thr is threonine, Phe is phenylalanine, Leu is leucine and lieu is isoleucine, the amino acids having the L configuration unless otherwise stated, are prepared by hydrolysing a polymyxin of Formula III wherein K is an n-octanoyl, L-6-methyloctanoyl or 6-methylheptanoyl radical, G and Dab are as above, and either (1) Y-Z is D-Leu-Thr and X is D-Dab or D-Serine, or (2) Y-Z is D-Phe- Leu or D-Leu-Leu and X is Dab, or when K is L-6-methyloctanoyl or 6-methylheptanoyl then Y-Z may be D-Leu-Ileu and X is Dab, and when X is Dab it optionally has a group G on the γ-amino group, by an enzyme which is a protease from B. subtilis A.T.C.C. 9524 or an exocellular protease from any appropriate strain of B. subtilis. The preferred enzymes are subtilisin, nagarse, pronase, colistinase or Alcalase (Registered Trade Mark). The compounds of Formula I are useful as intermediates for synthesizing polymyxin analogues having a modified side chain by reacylating the α-amino group on the Dab with an appropriate acid radical, and subsequently removing the protective groups G from the other amino groups e.g. by hydrogenolysis. The starting materials of Formula III are prepared by reacting a polymyxin e.g. colistin, polymyxin B, with a mixed carbonate of Formula V below suitably in an organic solvent such as dimethyl-formamide at 15‹ to 60‹ C. If desired the pyridyl group may be oxidized to the N-oxide before or after the reaction e.g. with p-nitroperbenzoic acid. Compounds having the general Formula V wherein Py is as hereinbefore defined and T is phenyl, substituted phenyl (e.g. p-nitrophenyl; 2,4,5-trichlorophenyl) or a heterocyclic radical (e.g. 8-quinolinyl or 2,5-dioxopyrrolidin-1-yl) are prepared by reacting an alcohol of formula Py-CH 2 -OH with a chloroformate of formula Cl-CO-O-T, and if required oxidizing the pyridyl radical to pyridyl-N-oxide, e.g. with p-nitroperbenzoic acid.
Subject polymers have a plurality of repeating units having amino-bis-phosphonate functionality pendent groups of a polyacrylate, polymethacrylate, polyacrylamide, polymethacrylamide, or linear polyethyleneimine. The polymers are prepared from a plurality of monomers comprising amino-te-phosphonate functionality or from a polymer having NHBoc or active ester pendent groups that are subsequently transformed into the amino-bis-phosphonate comprising polymer. The amino-bis-phosphonate comprising polymers or their precursor polymers can be prepared by RAFT polymerization or by transformation of a preformed polymer. The amino-bis-phosphonate comprising polymers can be linear or branched polymers. The amino-bis-phosphonate comprising polymers can be complexed with metal ions. The metal ions can be a radionuclide and the amino-bis-phosphonate comprising polymer complexes can be used as radiotherapeutic agents.
This study includes the use of Idelalisib to treat previously treated patients with IgM-associated AL Amyloidosis at Boston Medical Center. Boston Medical Center is internationally recognized as a leader in amyloidosis research and patient care through the activities of the multidisciplinary Amyloid Center at Boston University. The problematic cell in most forms of AL amyloidosis shares similarities with multiple myeloma. However, in the small subset of AL Amyloidosis patients with an IgM paraprotein, the cells are more typically related to lymphoplasmacytic lymphoma or Waldenstrom's macroglobulinemia. Because clonal cluster of differentiation antigen 20 (CD20)+ lymphoplasmacytic cells are usually responsible for IgM paraproteins, treatment paradigms based on Waldenstrom's macroglobulinemia (WM) may be more appropriate than myeloma-based strategies. Idelalisib has been shown to be active and well tolerated in patients with relapsed/refractory non-Hodgkin lymphoma including chronic lymphocytic lymphoma, and lymphoplasmacytic lymphoma with or without Waldenström's macroglobulinemia (WM). The side effect profile of idelalisib merges well with the known predisposition to toxicity of amyloidosis patient.

The investigators expect to enroll 15 participants with IgM-associated AL amyloidosis onto this Phase II clinical trial. Idelalisib will be self-administered orally at a dose of 100 mg (1 tablet) twice daily (may be escalated to 150 mg (one tablet) twice daily after 3 months at investigator discretion). Participants will be treated until disease progression, unacceptable toxicity, or decision to withdraw from the trial. Disease evaluations will be performed every three months until disease progression.
A computer implemented method for generating personalized responsive assistance for a person needing assistance (PNA) is disclosed. The method begins with the system receiving a PNA's contact data and a trust group manager's (TGM) contact data. The system then sends a request to the TGM for association of TGM's device with PNA's device. The system then receives approval and proceeds with storing an indicator of the association of the devices. The TGM then sends the system a person providing assistance's (PPA) data. The system will then send an invite to the PPA, to join a trust group associated with the PNA. After the PPA accepts the invite to join the PPA group, the system will receive a request for an audio/visual connection between the PNA and the PPA. As the PNA is in need of assistance, an audio/visual connection will be permitted allowing the PPA to help the PNA.
If allocated to the placebo arm, the child will be given a similar appearing medication; the placebo will be a sugar pill. All patients will receive either study drug or placebo for a total of 20 days.
Many times each day, we see food or representations of food and evaluate whether or not the food looks good to us. If it does, we then balance external factors, such as the social situation or time of day, against internal signals about our hunger state in order to decide what and when to eat. However, recent functional magnetic resonance imaging (fMRI) studies suggest that internal signals, such as hormones regulating appetite and satiety, govern our food intake in part by acting on neural circuits to affect whether a given food appears appetizing at that moment. In addition, photographs of food perceived to be "fattening" activate brain regions involved in appetite and reward processing, including the hypothalamus, nucleus accumbens, and orbital frontal cortex. This activity is potently reduced by food intake, suggesting that it reflects underlying brain mechanisms involved in satiety. We now propose to study the mechanism of these changes in brain activity by asking if they are directly related to the action of glucagon-like peptide-1 (GLP-1), a satiety signal. GLP-1 is released by cells in the gut in response to nutrients, suppressing food intake, and its actions can be blocked by a GLP-1 receptor antagonist, exendin-\[9-39\]. In 2 randomized, controlled, crossover studies, we will assess whether exendin-\[9-39\] infusions reverse GLP-1-mediated effects on food intake and on brain response to visual food cues. Our scientific aims are to 1) observe the effect of exendin (9-39) on blocking GLP-1-mediated satiety in humans and assess its effect on food intake in humans for the first time (to our knowledge) and 2) to test whether endogenous GLP-1 signaling is required for the effect of a meal to reduce brain response to visual food cues in humans. We hypothesize that exendin-\[9-39\] will diminish the effect of a meal in suppressing subsequent food intake and in reducing activation to visual food cues in reward pathways. Determining the extent to which the experience of satiety arises from a decrease in the reward value of food is fundamentally important to understanding human feeding behavior. In addition, this promising line of research is directly relevant to some of the most pressing public health issues of our time: obesity and overnutrition. We hope that investigating mechanisms affecting our perception of satiety at the most basic level will eventually result in novel behavioral or pharmacologic strategies for obesity prevention and treatment.
Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unexpected toxicity. Patients also receive interferon gamma-1b SC 3 times per week for 12 weeks, and then follow 3 weeks on and 3 weeks off schedule for up to 2 years in the absence of disease progression or unexpected toxicity.